177 related articles for article (PubMed ID: 30538442)
61. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
62. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
63. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer.
Wu M; Zhao J; Song SW; Zhuo M; Wang X; Bai H; Wang S; Yang L; An T; Zhang Y; Duan J; Wang Y; Guo Q; Liu X; Liu N; Wang J
Lung Cancer; 2010 Mar; 67(3):343-7. PubMed ID: 19477549
[TBL] [Abstract][Full Text] [Related]
64. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
[TBL] [Abstract][Full Text] [Related]
65. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
66. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
67. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
Jo J; Kim SH; Kim YJ; Lee J; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Chung JH; Jeon YK; Lee JS
Yonsei Med J; 2018 Mar; 59(2):202-210. PubMed ID: 29436187
[TBL] [Abstract][Full Text] [Related]
69. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
70. Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.
Yi Y; Liu Z; Fang L; Li J; Liu W; Wang F; Fu P; Xie C; Liu J; Song B
Cancer Chemother Pharmacol; 2020 Jul; 86(1):65-74. PubMed ID: 32533335
[TBL] [Abstract][Full Text] [Related]
71. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
72. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
73. [A retrospective study of the impact of diabetes mellitus on survival in patients with lung cancer].
Han R; Yang G; Lyu Z; Gu W; Du J; Jin N; Zang L; Yang L; Guo Q; Ba J; Dou J; Mu Y
Zhonghua Nei Ke Za Zhi; 2015 Dec; 54(12):1028-31. PubMed ID: 26887369
[TBL] [Abstract][Full Text] [Related]
74. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
[No Abstract] [Full Text] [Related]
75. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
76. Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity.
Wang W; Dou S; Dong W; Xie M; Cui L; Zheng C; Xiao W
Int J Chron Obstruct Pulmon Dis; 2018; 13():3767-3776. PubMed ID: 30538439
[TBL] [Abstract][Full Text] [Related]
77. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
78. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Wang J; Wu N; Lv C; Yan S; Yang Y
J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
[TBL] [Abstract][Full Text] [Related]
79. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer.
Younes RN; Pereira JR; Fares AL; Gross JL
Rev Assoc Med Bras (1992); 2011; 57(6):686-91. PubMed ID: 22249550
[TBL] [Abstract][Full Text] [Related]
80. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
Ann Oncol; 2015 Sep; 26(9):1877-1883. PubMed ID: 26141208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
